Etocarlide

Etocarlide

SCHEMBL3895833

CCOc1ccc(NC(=S)Nc2ccc(OCC)cc2)cc1.[AlH3].[MgH2]

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.93
GAA P10253 5/20 0.81
L3MBTL1 Q9Y468 1/20 0.71
ALDH1A1 P00352 8/20 0.66
KDM4E B2RXH2 2/20 0.66
LMNA P02545 5/20 0.65
KMT2A Q03164 5/20 0.62
MEN1 O00255 3/20 0.62
HTT P42858 3/20 0.62
POLB P06746 2/20 0.62
HPGD P15428 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
NSD2 O96028 1/20 0.62
BLM P54132 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
MPI P34949 1/20 0.61
CYP1A2 P05177 1/20 0.61
TDP1 Q9NUW8 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Etocarlide SCHEMBL122903 0.98 MAPT (0.96) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL27611 0.98 MAPT (0.96) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL2995239 0.96 MAPT (0.93) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL11074653 0.96 MAPT (0.93) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL9367891 0.96 MAPT (0.93) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL6513773 0.96 MAPT (0.93) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL103618 0.96 MAPT (1.00) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL9263 0.96 MAPT (1.00) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL250651 0.95 MAPT (0.89) MAPTGAAL3MBTL1ALDH1A1KDM4E
Etocarlide SCHEMBL29187 0.94 MAPT (0.96) MAPTGAAL3MBTL1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116814041-A Waterproof flame-retardant cable 瑞鑫集团有限公司 2023-09-29 CN claimed
EP-0031805-B1 HARD BODY, ESPECIALLY HARD METAL WEARING PART, AND PROCESS FOR ITS PRODUCTION VEREINIGTE EDELSTAHLWERKE AKTIENGESELLSCHAFT (VEW) (AT) 1984-09-19 EP claimed
CN-116814041-A Waterproof flame-retardant cable 瑞鑫集团有限公司 2023-09-29 CN disclosed
US-11306085-B2 Method for preparing pyrimidone heteroaryl derivative and intermediate of pyrimidone heteroaryl derivative JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2022-04-19 US disclosed
CN-113388319-B High-wear-resistance chair 宁波市鑫晟工贸实业有限公司 2022-04-15 CN disclosed
CN-109748303-B Preparation method of high-purity spherical magnesia-alumina spinel nano-powder 大连交通大学 2022-02-08 CN disclosed
CN-109983017-B Preparation method and intermediate of pyrimidone heteroaryl derivative 江苏恒瑞医药股份有限公司 2021-11-12 CN disclosed
CN-113388319-A High-wear-resistance chair 宁波市鑫晟工贸实业有限公司 2021-09-14 CN disclosed
CN-112042005-A Separator having a separator layer comprising ceramic 新罗纳米技术有限公司 2020-12-04 CN disclosed
EP-3660017-A1 METHOD FOR PREPARING PYRIMIDONE HETEROARYL DERIVATIVE AND INTERMEDIATE OF PYRIMIDONE HETEROARYL DERIVATIVE Jiangsu Hengrui Medicine Co., Ltd. (CN) 2020-06-03 EP disclosed
US-20200140434-A1 METHOD FOR PREPARING PYRIMIDONE HETEROARYL DERIVATIVE AND INTERMEDIATE OF PYRIMIDONE HETEROARYL DERIVATIVE JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2020-05-07 US disclosed
EP-1051461-A2 FUEL COMPOSITIONS EMPLOYING CATALYST COMBUSTION STRUCTURE ORR, William C. (US) 2000-11-15 EP disclosed
WO-1999066009-A2 FUEL COMPOSITIONS EMPLOYING CATALYST COMBUSTION STRUCTURE ORR WILLIAM C (US) 1999-12-23 WO disclosed
EP-0954558-A1 FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY ORR, William C. (US) 1999-11-10 EP disclosed
WO-1998026028-A1 FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY ORR WILLIAM C (US) 1998-06-18 WO disclosed
US-5068291-A Method of preparing pressure sensitive adhesives with accelerated cure rate NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) 1991-11-26 US disclosed
EP-0183495-A1 Pressure sensitive adhesives BP Chemicals Limited (GB) 1986-06-04 EP disclosed
US-4430257-A MIXING WITH GLASS-FORMING, PARTIALLY HYDROLYZED SILICON AND METAL COMPOUND MIXTURE THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) 1984-02-07 US disclosed
US-4292231-A CARBOXY AND CARBAMATE-FUNCTIONAL VINYL INTERPOLYMER ASHLAND OIL, INC. (US) 1981-09-29 US disclosed
US-4005247-A ACRYLATE INTERPOLYMER, METAL ALKOXIDE ASHLAND OIL, INC. (US) 1977-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11306085-B2 Method for preparing pyrimidone heteroaryl derivative and intermediate of pyrimidone heteroaryl derivative TYMP, UMPS, DPYD MAPT 3916/4885GAA 1647/4885L3MBTL1 4657/4885
US-20200140434-A1 METHOD FOR PREPARING PYRIMIDONE HETEROARYL DERIVATIVE AND INTERMEDIATE OF PYRIMIDONE HETEROARYL DERIVATIVE UMPS, TYMP, DHPS MAPT 4062/4885GAA 1187/4885L3MBTL1 4550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.